NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Inavolisib with palbociclib and fulvestrant for treating hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after adjuvant endocrine treatment ID6425

Final Stakeholder List

Consultees	**Commentators (no right to submit or appeal)**
Company • Roche (inavolisib) Patient/carer groups • Black Health Agency for Equality • Breast Cancer Now • Breast Cancer UK • Cancer Black Care • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Inflammatory Breast Cancer (IBC) Network UK • Lobular Breast Cancer UK • Macmillan Cancer Support • Maggie's Centres • Make 2nds Count • Marie Curie • MET UP UK • Prevent Breast Cancer • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care Healthcare professional groups • Association of Breast Surgery • Association of Cancer Physicians • British Geriatrics Society • British Institute of Radiology • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Society of Interventional Radiology	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • • AstraZeneca (fulvestrant) • Dr. Reddy's Laboratories (fulvestrant) • Eli Lilly (abemaciclib) • Genus Pharmaceuticals (fulvestrant) • Medical Valley Invest AB (fulvestrant) • Novartis (ribociclib) • Pfizer (palbociclib) • Ranbaxy (fulvestrant) • Sandoz (fulvestrant) • Sun Pharmaceutical Industries Europe B.V. (fulvestrant)

© National Institute for Health and Care Excellence 2025. All rights reserved.

Consultees	**Commentators (no right to submit or appeal)**
• Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Breast Cancer Group • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England	• Teva UK (fulvestrant) • Zentiva (fulvestrant) <u>Relevant research groups</u> • Against Breast Cancer • Breast Cancer Hope • Cochrane Breast Cancer Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research • Pro-Cancer Research Fund <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency <u>Evidence Review Group</u> •

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

© National Institute for Health and Care Excellence 2025. All rights reserved.

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

© National Institute for Health and Care Excellence 2025. All rights reserved.